Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany, and Singapore investing in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. The current team consists of 30 life sciences investment professionals with successful investments in over 92 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Forbion operates a joint venture with BGV, the manager of seed and earlystage funds, especially focused on Benelux and Germany.
Scope: All stages; Therapeutics
Ticket size: ~€15-25M, with up to ~€35-50M over the life of a company
Geography: Worldwide with a strong focus on Europe
One-on-ones with the speaker are a great chance to ask individual questions and connect. Only available for startups that are currently looking for venture capital investment.